BP000051-GD14: Recombinant Human OPG-Fc Fusion Protein
Source: HEK 293-derived.
The Osteoprotegerin / OPG / TNFRSF11B / OCIF / OBF activity is calculated by its ability to inhibit TRAIL-mediated cytotoxicity using L929 mouse fibrosarcoma cells treated with TRAIL. The ED50 for this effect is typically 5 ng/ml.
Endotoxin: < 5.0 EU per 1 ug of the protein by the LAL method.
Purity: > 90% by SDS-PAGE and RP-HPLC.